Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Vogl

Showing results (321-330 of 342) with videos related to

Pageof 35
Sort By:
Blood|June 22, 2011
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisShaji Kumar, Mei-Jie Zhang, Peigang Li, et al.
Radiation and Environmental Biophysics|January 9, 2015
Risk of cancer incidence before the age of 15 years after exposure to ionising radiation from computed tomography: results from a German cohort studyL Krille, S Dreger, R Schindel, et al.
Science Immunology|April 19, 2017
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patientsThomas Condamine, George A Dominguez, Je-In Youn, et al.
Transplantation and Cellular Therapy|June 16, 2026
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall SurvivalGurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2022
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic MalignanciesMark A Dawson, Gautam Borthakur, Brian J P Huntly, et al.
JCI Insight|March 5, 2019
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyAnita D'Souza, Angela Dispenzieri, Baldeep Wirk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 4, 2015
New cancers after autotransplantations for multiple myelomaAnuj Mahindra, Girindra Raval, Paulette Mehta, et al.
JCI Insight|April 20, 2018
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
Pageof 35

Showing results (321-330 of 342) with videos related to

Sort By:
Pageof 35
Blood|June 22, 2011
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisShaji Kumar, Mei-Jie Zhang, Peigang Li, et al.
Radiation and Environmental Biophysics|January 9, 2015
Risk of cancer incidence before the age of 15 years after exposure to ionising radiation from computed tomography: results from a German cohort studyL Krille, S Dreger, R Schindel, et al.
Science Immunology|April 19, 2017
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patientsThomas Condamine, George A Dominguez, Je-In Youn, et al.
Transplantation and Cellular Therapy|June 16, 2026
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall SurvivalGurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2022
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic MalignanciesMark A Dawson, Gautam Borthakur, Brian J P Huntly, et al.
JCI Insight|March 5, 2019
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyAnita D'Souza, Angela Dispenzieri, Baldeep Wirk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 4, 2015
New cancers after autotransplantations for multiple myelomaAnuj Mahindra, Girindra Raval, Paulette Mehta, et al.
JCI Insight|April 20, 2018
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
Pageof 35